Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...
7d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...
In a rapidly changing climate landscape, the plants we rely on for food, textiles and more face a multitude of challenges, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results